Considering the potential of the metabolic drugs as treatment options for MeCP2-linked neurodevelopmental disorders, the focus of our review is to discuss the impacted cellular metabolism in MeCP2-associated diseases, focusing on RTT. Here, MECP2 is linked to neurodevelopmental disorder.